alanine has been researched along with Adverse Drug Event in 22 studies
Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.
alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To describe the occurrence of adverse events in PD patients treated with safinamide in real-life conditions." | 3.01 | A European Observational Study to Evaluate the Safety and the Effectiveness of Safinamide in Routine Clinical Practice: The SYNAPSES Trial. ( Abbruzzese, G; Bergmans, B; Gomez-Esteban, JC; Jost, WH; Kägi, G; Kulisevsky, J; Raw, J; Stefani, A; Warnecke, T, 2021) |
| " Treatment-emergent adverse events (TEAEs) are reported by body system along with pertinent laboratory, vital sign, and ECG findings." | 2.79 | Safety profile of semagacestat, a gamma-secretase inhibitor: IDENTITY trial findings. ( Dowsett, SA; Henley, DB; May, PC; Sethuraman, G; Sundell, KL, 2014) |
| "Aphthous stomatitis is induced by chemotherapy and radiotherapy." | 2.61 | [Development of Hospital Formulations Based on Medical Need]. ( Hanawa, T; Kawano, Y, 2019) |
| "Long-term treatment of chronic hepatitis B (CHB) with nucleos(t)ide analogues is often necessary to achieve durable viral suppression." | 2.58 | Long-term safety and efficacy of nucleo(t)side analogue therapy in hepatitis B. ( Buti, M; Esteban, R; Riveiro-Barciela, M, 2018) |
| "We aimed to assess longitudinal changes in clinical indexes of corona disease 2019 (Covid-19) patients with mild pulmonary infection during 5 days of remdesivir therapy and determine the effect of age and gender on remdesivir adverse effects (AE)." | 1.72 | Linear mixed model analysis to evaluate correlations between remdesivir adverse effects with age and gender of patients with mild Covid-19 pneumonia. ( Amanollahi, A; Basir Ghafouri, H; Hoseini, SE; Moradi Moghaddam, O; Sedighi, M; Tavakoli, N, 2022) |
| "To evaluate the cumulative incidence (CI) of suspected adverse drug reactions (ADR) from TCZ in adult patients with COVID-19." | 1.72 | [Surveillance of adverse effects of Tocilizumab for COVID-19]. ( Fuenzalida, T; González, A; Gutiérrez, W; Iturra, P; Severino, N, 2022) |
| " To exclude toxic concentrations of potential drugs, the network was expanded to include a toxic score (TOX) that detected cell death (CPETOXnet)." | 1.62 | Deep Transfer Learning Approach for Automatic Recognition of Drug Toxicity and Inhibition of SARS-CoV-2. ( Bhatia, S; Borkhardt, A; Kather, JN; Kronberg, RM; Lang, KS; Lang, PA; Müller, L; Ostermann, PN; Pandyra, AA; Schaal, H; Stachura, P; Werner, J, 2021) |
| " Harms are typically assessed through the collection of adverse events (AEs)." | 1.56 | Advantages of visualisations to evaluate and communicate adverse event information in randomised controlled trials. ( Cornelius, V; Cro, S; Phillips, R, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (36.36) | 24.3611 |
| 2020's | 14 (63.64) | 2.80 |
| Authors | Studies |
|---|---|
| Yang, BR | 1 |
| Lee, JY | 1 |
| Kim, MG | 1 |
| Sullivan, JT | 1 |
| Sedighi, M | 1 |
| Amanollahi, A | 1 |
| Moradi Moghaddam, O | 1 |
| Basir Ghafouri, H | 1 |
| Hoseini, SE | 1 |
| Tavakoli, N | 1 |
| Severino, N | 1 |
| Gutiérrez, W | 1 |
| Fuenzalida, T | 1 |
| Iturra, P | 1 |
| González, A | 1 |
| Kawano, Y | 1 |
| Hanawa, T | 1 |
| Zekarias, A | 1 |
| Watson, S | 1 |
| Vidlin, SH | 1 |
| Grundmark, B | 1 |
| Schwartz, RA | 1 |
| Sharma, A | 1 |
| Szepietowski, JC | 1 |
| Sandhu, S | 1 |
| Goldust, M | 1 |
| Abbruzzese, G | 1 |
| Kulisevsky, J | 1 |
| Bergmans, B | 1 |
| Gomez-Esteban, JC | 1 |
| Kägi, G | 1 |
| Raw, J | 1 |
| Stefani, A | 1 |
| Warnecke, T | 1 |
| Jost, WH | 1 |
| Cornelius, V | 1 |
| Cro, S | 1 |
| Phillips, R | 1 |
| Falcão, F | 1 |
| Viegas, E | 1 |
| Carmo, I | 1 |
| Soares, J | 1 |
| Falcao, M | 1 |
| Solano, M | 1 |
| Cavaco, P | 1 |
| Mendes, D | 1 |
| Rijo, J | 1 |
| Povoa, P | 1 |
| Pais Martins, A | 1 |
| Carmo, E | 1 |
| Mansinho, K | 1 |
| Fonseca, C | 1 |
| Campos, L | 1 |
| Carvalho, A | 1 |
| Mirco, A | 1 |
| Farinha, H | 1 |
| Aldir, I | 1 |
| Correia, J | 1 |
| Mantripragada, AS | 1 |
| Teja, SP | 1 |
| Katasani, RR | 1 |
| Joshi, P | 1 |
| V, M | 1 |
| Ramesh, R | 1 |
| Chouchana, L | 1 |
| Preta, LH | 1 |
| Tisseyre, M | 1 |
| Terrier, B | 1 |
| Treluyer, JM | 1 |
| Montastruc, F | 1 |
| Werner, J | 1 |
| Kronberg, RM | 1 |
| Stachura, P | 1 |
| Ostermann, PN | 1 |
| Müller, L | 1 |
| Schaal, H | 1 |
| Bhatia, S | 1 |
| Kather, JN | 1 |
| Borkhardt, A | 1 |
| Pandyra, AA | 1 |
| Lang, KS | 1 |
| Lang, PA | 1 |
| Kim, MS | 1 |
| Jung, SY | 1 |
| Lee, SW | 1 |
| Li, H | 1 |
| Koyanagi, A | 1 |
| Kronbichler, A | 1 |
| Dragioti, E | 1 |
| Tizaoui, K | 1 |
| Wasuwanich, P | 1 |
| Hong, SH | 1 |
| Ghayda, RA | 1 |
| Yoo, HW | 1 |
| Kim, H | 1 |
| Jacob, L | 1 |
| Salem, JE | 1 |
| Kostev, K | 1 |
| Shin, YH | 1 |
| Kim, SY | 1 |
| Gamerith, G | 1 |
| Yon, DK | 1 |
| Shin, JI | 1 |
| Smith, L | 1 |
| Singh, A | 1 |
| Kamath, A | 1 |
| Buti, M | 1 |
| Riveiro-Barciela, M | 1 |
| Esteban, R | 1 |
| Hodder, S | 1 |
| Squires, K | 1 |
| Kityo, C | 1 |
| Hagins, D | 1 |
| Avihingsanon, A | 1 |
| Kido, A | 1 |
| Jiang, S | 1 |
| Kulkarni, R | 1 |
| Cheng, A | 1 |
| Cao, H | 1 |
| Shafran, SD | 1 |
| Di Perri, G | 2 |
| Esser, S | 1 |
| Lelièvre, JD | 1 |
| Parczewski, M | 1 |
| Henley, DB | 1 |
| Sundell, KL | 1 |
| Sethuraman, G | 1 |
| Dowsett, SA | 1 |
| May, PC | 1 |
| Antela, A | 1 |
| Aguiar, C | 1 |
| Compston, J | 1 |
| Hendry, BM | 1 |
| Boffito, M | 1 |
| Mallon, P | 1 |
| Pourcher-Martinez, V | 1 |
| Gazzard, B | 1 |
| Sipp, D | 1 |
| McCabe, C | 1 |
| Rasko, JE | 1 |
5 reviews available for alanine and Adverse Drug Event
| Article | Year |
|---|---|
[Development of Hospital Formulations Based on Medical Need].
Topics: Alanine; Cellulose; Chemical Phenomena; Drug Compounding; Drug-Related Side Effects and Adverse Reac | 2019 |
Systemic Medications of Dermatological Importance in COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Biological Products; Coronavirus Infections; COV | 2020 |
Long-term safety and efficacy of nucleo(t)side analogue therapy in hepatitis B.
Topics: Adenine; Administration, Oral; Alanine; Antiviral Agents; Drug-Related Side Effects and Adverse Reac | 2018 |
Planning HIV therapy to prevent future comorbidities: patient years for tenofovir alafenamide.
Topics: Adenine; Age Factors; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Clinical Tria | 2019 |
The role of tenofovir alafenamide in future HIV management.
Topics: Adenine; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug-Related Side Effects | 2016 |
3 trials available for alanine and Adverse Drug Event
| Article | Year |
|---|---|
A European Observational Study to Evaluate the Safety and the Effectiveness of Safinamide in Routine Clinical Practice: The SYNAPSES Trial.
Topics: Aged; Aged, 80 and over; Alanine; Benzylamines; Comorbidity; Drug-Related Side Effects and Adverse R | 2021 |
Brief Report: Efficacy and Safety of Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide (E/C/F/TAF) in Virologically Suppressed Women.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cobicistat; Double- | 2018 |
Safety profile of semagacestat, a gamma-secretase inhibitor: IDENTITY trial findings.
Topics: Aged; Alanine; Alzheimer Disease; Amyloid Precursor Protein Secretases; Azepines; Clinical Trials, P | 2014 |
14 other studies available for alanine and Adverse Drug Event
| Article | Year |
|---|---|
The risk of pulmonary adverse drug reactions of rebamipide and other drugs for acid-related diseases: An analysis of the national pharmacovigilance database in South Korea.
Topics: Adverse Drug Reaction Reporting Systems; Aged; Alanine; Databases, Factual; Drug-Related Side Effect | 2022 |
Postmarketing pharmacovigilance: Remdesivir and cardiovascular events.
Topics: Adenosine Monophosphate; Alanine; Cardiovascular Diseases; Drug-Related Side Effects and Adverse Rea | 2022 |
Linear mixed model analysis to evaluate correlations between remdesivir adverse effects with age and gender of patients with mild Covid-19 pneumonia.
Topics: Adenosine Monophosphate; Alanine; COVID-19 Drug Treatment; Creatinine; Drug-Related Side Effects and | 2022 |
[Surveillance of adverse effects of Tocilizumab for COVID-19].
Topics: Adolescent; Adult; Alanine; Antibodies, Monoclonal, Humanized; Aspartate Aminotransferases; COVID-19 | 2022 |
Sex Differences in Reported Adverse Drug Reactions to COVID-19 Drugs in a Global Database of Individual Case Safety Reports.
Topics: Abdominal Pain; Adenosine Monophosphate; Alanine; Antibodies, Monoclonal, Humanized; Antiviral Agent | 2020 |
Advantages of visualisations to evaluate and communicate adverse event information in randomised controlled trials.
Topics: Adenosine Monophosphate; Alanine; Antiparkinson Agents; Antiviral Agents; Computer Graphics; COVID-1 | 2020 |
A prospective, observational study to evaluate adverse drug reactions in patients with COVID-19 treated with remdesivir or hydroxychloroquine: a preliminary report.
Topics: Adenosine Monophosphate; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Al | 2021 |
Prediction of adverse drug reactions using drug convolutional neural networks.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; COVID-19 Drug Treatment; Databases, Pharmaceutic | 2021 |
Kidney disorders as serious adverse drug reactions of remdesivir in coronavirus disease 2019: a retrospective case-noncase study.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; COVID-19 Drug Treatment; Drug-Related Side Effec | 2021 |
Deep Transfer Learning Approach for Automatic Recognition of Drug Toxicity and Inhibition of SARS-CoV-2.
Topics: Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Chlorocebus aethiops; Coronavirus Nucle | 2021 |
Hepatobiliary Adverse Drug Reactions Associated With Remdesivir: The WHO International Pharmacovigilance Study.
Topics: Adenosine Monophosphate; Adverse Drug Reaction Reporting Systems; Alanine; COVID-19 Drug Treatment; | 2021 |
Assessment of adverse events associated with remdesivir use for coronavirus disease 2019 using real-world data.
Topics: Acute Kidney Injury; Adenosine Monophosphate; Adverse Drug Reaction Reporting Systems; Alanine; Anti | 2021 |
Editorial.
Topics: Adenine; Alanine; Anti-HIV Agents; Clinical Trials as Topic; Drug Approval; Drug-Related Side Effect | 2016 |
Show drugs work before selling them.
Topics: Alanine; Azepines; Child; Clinical Trials as Topic; Drug Approval; Drug-Related Side Effects and Adv | 2017 |